Oxygen tension and a pharmacological switch in the regulation of transgene expression for gene therapy

Journal of Gene Medicine

Volumn 3, Issue 5, 2001, Pages 498-504

  Payen, E ^a   Bettan, M ^b   Henri, A ^a   Tomkiewitcz, E ^a   Houque, A ^a   Kuzniak, I ^a   Zuber, J ^a   Scherman, D ^b   Beuzard, Y ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; LUCIFERASE; OXYGEN; PRIMER DNA; TETRACYCLINE;

ADENOVIRUS; ANIMAL; ANOXIA; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; LEWIS CARCINOMA; LUNG TUMOR; METABOLISM; MOUSE; TRANSGENE;

ADENOVIRIDAE; ANIMALS; ANOXIA; CARCINOMA, LEWIS LUNG; DNA PRIMERS; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; LUCIFERASES; LUNG NEOPLASMS; MICE; OXYGEN; TETRACYCLINE; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSGENES;

EID: 0035459090     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.217     Document Type: Article

References (45)

1. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999; 96: 4262-4267.
2. Athanasopoulos T, Fabb S, Dickson G. Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases. Int J Mol Med 2000; 6: 363-375.
3. Rossi FM, Blau HM. Recent advances in inducible gene expression systems. Curr Opin Biotechnol 1998; 9: 451-456.
4. Tiedge M, Elsner M, McClenaghan NH, et al. Engineering of a glucose-responsive surrogate cell for insulin replacement therapy of experimental insulin-dependent diabetes. Hum Gene Ther 2000; 11: 403-414.
5. Rinsch C, Regulier E, Deglon N, et al. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 1997; 8: 1881-1889.
6. Varley AW, Munford RS. Physiologically responsive gene therapy. Mol Med Today 1998; 4: 445-451.
7. Semenza GL, Agani F, Feldser D, et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol 2000; 475: 123-130.
8. Ratcliffe PJ, O'Rourke JF, Maxwell PH, et al. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998; 201: 1153-1162.
9. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993; 90: 4304-4308.
10. Salceda S, Caro J. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions - its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 22642-22647.
11. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95: 7987-7992.
12. Kallio PJ, Wilson WJ, O'Brien S, et al. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999; 274: 6519-6525.
13. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-520.
14. Prentice H, Bishopric NH, Hicks MN, et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc Res 1997; 35: 567-574.
15. Binley K, Iqball S, Kingsman A, et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999; 6: 1721-1727.
16. Boast K, Binley K, Iqball S, et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999; 10: 2197-2208.
17. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000; 7: 493-498.
18. Koshikawa N, Takenaga K, Tagawa M, et al. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000; 60: 2936-2941.
19. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89: 5547-5551.
20. Shockett P, Difilippantonio M, Hellman N, et al. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci U S A 1995; 92: 6522-6526.
21. Firth JD, Ebert BL, Pugh CW, et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci U S A 1994; 91: 6496-6500.
22. Pugh CW, O'Rourke JF, Nagao M, et al. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 1997; 272: 11205-11214.
23. Resnitzky D, Gossen M, Bujard H, et al. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14: 1669-1679.
24. Naffakh N, Henri A, Villeval JL, et al. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci U S A 1995; 92: 3194-3198.
25. Dalle B, Payen E, Beuzard Y. Modulation of transduced erythropoietin expression by iron. Exp Hematol 2000; 28: 760-764.
26. Kreiss P, Bettan M, Crouzet J, et al. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1999; 1: 245-250.
27. Bettan M, Ivanov MA, Mir LM, et al. Efficient DNA electro-transfer into tumors. Bioelectrochemistry 2000; 52: 83-90.
28. Fishman GI, Kaplan ML, Buttrick PM. Tetracycline-regulated cardiac gene expression in vivo. J Clin Invest 1994; 93: 1864-1868.
29. Passman RS, Fishman GI. Regulated expression of foreign genes in vivo after germline transfer. J Clin Invest 1994; 94: 2421-2425.
30. Dhawan J, Rando TA, Elson SL, et al. Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle. Somat Cell Mol Genet 1995; 21: 233-240.
31. Bohl D, Naffakh N, Heard JM. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997; 3: 299-305.
32. Haberman RP, McCown TJ, Samulski RJ. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 1998; 5: 1604-1611.
33. Harding TC, Geddes BJ, Murphy D, et al. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol 1998; 16: 553-555.
34. Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 1999; 96: 6417-6422.
35. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529-32537.
36. Jiang BH, Zheng JZ, Leung SW, et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997; 272: 19253-19260.
37. Becker A, Hansgen G, Bloching M, et al. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998; 42: 35-41.
38. Movsas B, Chapman JD, Horwitz EM, et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999; 53: 11-18.
39. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6: 157-162.
40. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10: 695-712.
41. Vinogradov SA, Lo LW, Jenkins WT, et al. Noninvasive imaging of the distribution in oxygen in tissue in vivo using near-infrared phosphors. Biophys J 1996; 70: 1609-1617.
42. Lartigau E, Lespinasse F, Vitu L, et al. Does the direct measurement of oxygen tension in tumors have any adverse effects? Int J Radiat Oncol Biol Phys 1992; 22: 949-951.
43. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-1416.
44. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
45. Baron U, Gossen M, Bujard H. Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded trans-activation potential. Nucleic Acids Res 1997; 25: 2723-2729.